G6 Materials Valuation
Is G310 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of G310 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate G310's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate G310's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for G310?
Key metric: As G310 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is G310's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | US$1.17m |
| Market Cap | US$468.28k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | -0.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does G310's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
BIG1 Bio-Gate | 0.8x | 16.3% | €6.3m |
NSAK OTI Greentech | 0.03x | n/a | €571.0k |
BNN BRAIN Biotech | 1.3x | 8.5% | €70.8m |
NTG Nabaltec | 0.6x | 5.1% | €122.3m |
G310 G6 Materials | 0.4x | n/a | €654.7k |
Price-To-Sales vs Peers: G310 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does G310's PS Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Sales vs Industry: G310 is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is G310's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate G310's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Stanmore Resources
AU$2.8b
Engages in the exploration, development, production, and sale of metallurgical coal in Australia.
S0D
AU$1.88
7D
0.5%
1Y
-16.8%
Tokuyama
JP¥197.6b
Produces and sells various chemical products in Japan.
TBT
JP¥16.70
7D
5.0%
1Y
16.0%
Mitsubishi Chemical Group
JP¥1.2t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥5.27
7D
2.9%
1Y
-8.1%